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INTRODUCTION
NK cell neoplasm is divided into nasal-type NK/T cell
lymphoma and aggressive NK cell leukemia (1). In contrast
to aggressive NK cell leukemia, nasal-type NK/T cell lym-
phoma is localized disease, and bone marrow involvement is
uncommon (2-4). Because tumor cells of NK/T cell lymphoma
are variable in their morphology and sometimes small and
monotonous (5), morphologic identification of neoplastic cells
in the bone marrow may be difficult unless the involvement
is extensive. As the patients with nasal-type NK/T cell lym-
phoma undergo aggressive clinical course even in patients
with low stage disease (3, 4), one may wonder as to whether
staging of NK/T cell lymphoma is accurate and minimal bone
marrow involvement by nasal-type NK/T cell lymphoma
can be excluded by routine histologic examination with cer-
tainty. EBV in situ hybridization (ISH) is a powerful tech-
nique in detecting Epstein-Barr virus (EBV) infection. Because
most tumor cells in nasal-type NK/T cell lymphomas are
infected by EBV (6-11), we retrospectively performed EBV
ISH on bone marrow biopsy specimens from 40 patients to
identify minimal infiltration of EBV-infected neoplastic cells
and evaluate the frequency of bone marrow involvement by
nasal-type NK/T cell lymphoma.
MATERIALS AND METHODS
Patient selection
During the period from January 1996 to May 2002, 40
patients were diagnosed to have extranodal NK/T cell lym-
phomas, nasal-type at Samsung Medical Center, Seoul, Korea.
Their clinical and laboratory records were reviewed. All
patients had undergone bone marrow biopsy for lymphoma
staging at the time of diagnosis.
Histologic examination
In all cases, hematoxylin eosin-stained bone marrow biopsies,
and aspiration smears were reviewed.
Immunohistochemical study
The bone marrow biopsy sections were stained with poly-
clonal antibody for CD3 (1:200, Novocastra, U.K.), mono-
clonal antibody for CD20 (1:500, Novocastra, U.K.), and
monoclonal antibody for CD56 (1:20, Monosan, Uden, The
Netherlands).
ISH for EBV on bone marrow biopsy specimen
Paraffin-embedded sections of the biopsy specimens were
deparaffinized with xylene, followed by the treatment with
proteinase K, and finally hybridized with fluorescein isoth-
iocynanate-conjugated EBV oligonucleotides (Novocastra,
U.K.) complementary to nuclear RNA protein of the EBER1
and EBER2 genes (4). Positive labeling was identified only
when cells showed nuclear staining with EBV oligonucleotide.
As negative controls, we used EBV negative lymphoid tissues
and the hybridization mixture without the EBV oligonu-
cleotides.
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Bone Marrow is Involved in Less than 10% of Patients with 
Nasal-Type NK/T Cell Lymphoma at Initial Diagnosis
To evaluate the frequency of bone marrow involvement by nasal-type NK/T cell
lymphoma, we retrospectively studied biopsy specimens from 40 patients by EBV
in situ hybridization (ISH). Three patients had marrow involvement at initial diagno-
sis (7.5%). In one patient (1/40, 2.5%), the disease in bone marrow was recognized
by routine morphological assessment, while two other patients had minimal involve-
ment of lymphoma cells which was recognized only by EBV in situ hybridization
(2/40, 5%). Two patients had a disseminated disease at diagnosis and died 6 days
and 214 days after diagnosis. One patient had diffuse colonic lesion and died 82
days later. In conclusion, marrow involvement in nasal NK/T cell lymphoma is infre-
quent at initial diagnosis, and EBV ISH is a useful technique for identifying the minor
subgroup of patients which have easily overlooked neoplastic involvement.
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RESULTS
Clinical features
The clinicopathologic data of 40 cases are summarized in
Table 1.
The series included 28 men and 12 women, with ages rang-
ing from 26 to 81 yr (mean, 45.8 yr). The primary sites of
the disease were the nasal cavity in the majority of the patients
(27/40, 67.5%), pharynx and larynx in 3, skin in 4, colon in
3, oral cavity in 2 and tongue in one.
The blood cell counts were normal at diagnosis in 20 patients
but mild anemia was seen in 14 patients, and leukocytosis
or leukocytopenia in 3 patients. Three patients had pancy-
topenia at diagnosis, and they underwent aggressive clinical
course. Unfortunately, they died within 6 months despite
chemotherapy or radiation therapy. One patient had concur-
rent prostatic cancer and NK/T cell lymphoma. Another
patient developed cholangiocarcinoma after the diagnosis of
NK/T cell lymphoma.
On routine staging, most patients had stage I disease (25/40,
65%), 7 had stage II, 1 stage III, and 5 stage IV at diagnosis.
Case
No.
Age
(yr)
Gender Initial stage Treatment
Outcome
(follow-up: day)
Involvement at presentation
BM involvement by NK/T cell lymphoma
H&E and IHC EBV ISH
1 43 M Nasal cavity I - - C+R A (1415)
2 40 F Skin (eyelid), liver, pancreas, IV + + C D (6)
BM, LN
3 47 F Nasal cavity I - - C A (547)
4 66 M Skin (foot) I - - C A (550)
5 59 M Skin (eyelid) I - - C A (375)
6 31 M Nasal cavity I - - C+R A (694)
7 81 M Skin (upper arm) NA - - NA NA
8 33 M Oral cavity, LN II - - C D (181)
9 37 M Nasal cavity I - - C A (1664)
10 45 M Nasal cavity I - - C+R A (1884)
11 26 M Nasal cavity, LN II - - C+PBSCT D (165)
12 39 M Larynx, brain, LN IV - - C D (194)
13 65 M Parynx I - - C D (25)
14 57 F Nasal cavity NA - - C+R D (143)
15 38 F Oral cavity, LN II - - C D (383)
16 35 M Nasal cavity I - - C+R D (166)
17 43 M Nasal cavity I - - C+R A (1289)
18 62 M Tongue I - - C Lost
19 34 M Nasal cavity I - - C A (1521)
20 45 M Nasal cavity, liver, spleen, LN IV - + C D (214)
21 54 M Nasal cavity I - - C+R D (444)
22 38 M Colon I - + S+C D (82)
23 32 F Oropharynx I - - C+R Lost
24 60 F Colon I - - S+C A (510)
25 43 M Nasal cavity I - - C D (79)
26 50 F Nasal cavity I - - C+R A (1253)
27 39 F Nasal cavity I - - C+R A (1854)
28 43 F Nasal cavity I - - C A (1676)
29 67 M Nasal cavity, LN II - - C D (72)
30 40 M Nasal cavity, abdominal LN III - - C+PBSCT D (796)
31 33 M Nasal cavity I - - C+R D (542)
32 35 M Colon, LN II - - C+R D (47)
33 34 M Nasal cavity I - - C+R D (185)
34 41 M Nasal cavity, LN II - - C D (63)
35 44 M Nasal cavity, LN II - - C+R D (144)
36 33 M Nasal cavity, liver IV - - C+R D (134)
37 57 M Nasal cavity, skin IV - - C+R D (270)
38 50 F Nasal cavity I - - C+R A (2150)
39 57 F Nasal cavity I - - C D (85)
40 59 F Nasal cavity I - - C A (150)
Table 1. Clinicopathologic findings of 40 patients with nasal-type NK/T cell lymphoma
ISH, in situ hybridization; F, female; M, male; C, chemotherapy; R, radiotherapy; S, surgery; PBSCT, peripheral blood stem cell transplantation; A,
alive; D, died; NA, not available; BM, bone marrow; LN, lymph node; IHC, immunohistochemistry.Nasal-Type NK/T Cell Lymphoma 231
Staging was not available in two patients.
Seventeen patients were treated with combined radiother-
apy and chemotherapy with cyclophosphamide, doxorubicin,
vincristine, prednisolone (CHOP) regimen. Twenty patients
were treated with chemotherapy alone, and 2 of them also
received autologous peripheral stem cell transplantation. Two
patients were treated with surgery followed by chemotherapy
due to intestinal perforation.
Out of 40 patients, follow-up information was available
in 37 patients. Twenty-two out of 37 patients (59.5%) died
of the disease 6 to 796 days later (mean, 200.9 days; median,
154.5 days). Eight out of 23 patients with stage I disease (34
%) died of the disease 25 to 542 days later (mean, 201 days;
median, 125.5 days). All 7 patients with stage II disease (100
%) died 47 days to 383 days later (mean, 150.7 days; medi-
an, 144 days). The patient with stage III died 796 days later
and all 5 patients with stage IV, 6 days to 270 days later (mean,
163.6 days; median, 194 days). One patient whose stage was
not known died of the disease 143 days later.
Detection of disease in the bone marrow
Among the bone marrow biopsy specimens obtained from
the patients for initial diagnosis, only 3 (7.5%) showed evi-
dence of involvement by NK/T cell lymphoma. In one patient,
the neoplastic involvement was recognized by hematoxylin-
eosin stain and immunohistochemistry for pCD3 as well as
EBV ISH (1/40, 2.5%) (Fig. 1). The patient had a dissemi-
nated disease involving the eye, liver, pancreas, and abdomi-
nal lymph node, and died 6 days after the diagnosis. In the
other two patients, the disease in the bone marrow was not
suspected by routine hematoxylin-eosin stain and immuno-
histochemistry for pCD3, but recognized by EBV ISH (2/
40, 5%) (Fig. 2). One of the last two patients showed dis-
seminated disease involving the liver, spleen, and nasophar-
ynx, and died 214 days after diagnosis. The other had diffuse
lesions confined to the colon and pursued aggressive clinical
course with colonic perforation but died 82 days after diag-
nosis.
DISCUSSION
The frequency of marrow involvement in non-Hodgkin’s
lymphomas at diagnosis is highly variable, ranging from as
low as 3% in primary mediastinal large B-cell lymphoma to
as high as 73% in B-cell small lymphocytic lymphoma/chronic
lymphocytic leukemia and lymphoplasmacytoid lymphoma
(12). It is generally higher in small cell lymphomas and fol-
licular lymphomas. The reported frequency of marrow involve-
ment by NK/T cell lymphoma is known to be low, and is
based on morphologic examination in most studies (4, 10).
However, morphologically normal marrow may harbor occult
lymphoma cells as revealed only by more sensitive techniques
for immunoglobulin or T-cell receptor gene rearrangements
(13, 14). For example, in the study by Fraga et al. (14), only
17% of the patients with anaplastic large cell lymphoma had
marrow involvement by conventional morphologic criteria,
while immunostaining for CD30 or epithelial membrane
antigen showed occult malignant cells in 23% of patients
with negative marrow on histologic examination. Likewise,
the morphologic identification of neoplastic involvement of
Fig. 1. Case 2 showing bone marrow involvement by NK/T cell lymphoma, which is identified by HE stain (A) as well as by EBV in-situ
hybridization (B).
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marrow by nasal-type NK/T cell lymphoma is difficult unless
the involvement is extensive. Isolated tumor cells can be easi-
ly overlooked, especially because the neoplastic cells are often
small to medium-sized.
In NK/T cell lymphoma, CD56 is a sensitive marker ex-
pressed in the majority of the cases. However it is of no use
in detecting tumor cells in the bone marrow biopsy speci-
mens, because decalcification process with acid destroys CD56
antigen on the cell surface. EBV ISH is a sensitive technique
because normal marrow rarely contains EBV-positive cells
(2, 15). In the present study, we determined the frequency
of lymphoma involvement of the marrow by nasal-type NK/T
cell lymphoma with the use of EBV ISH. The results con-
firm that marrow involvement by nasal type NK/T cell lym-
phoma is uncommon at diagnosis and EBV in situ hybridiza-
tion is a useful tool in detecting minimal infiltration of EBV
infected tumor cells.
Two patients with bone marrow involvement had dissem-
inated disease proven by clinical and radiologic studies at diag-
nosis, which suggests that bone marrow involvement in nasal-
type NK/T cell lymphoma is a late event in the course of dis-
ease. Another patient with bone marrow involvement had a
colonic disease and was initially diagnosed as stage I by Ann
Arbor Staging System (16). It is noteworthy that the lesion
Fig. 2. Case No. 20. NK/T cell lymphoma in bone marrow is not suspected by H&E stain (A) and immunohistochemical stain with CD 3 (B)
and CD56 (C), but detected by EBER in-situ hybridization (D).
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C Din the colon involved the entire colonic segments diffusely,
which indicates higher tumor burden than expected in the
estimated stage. 
Ann Arbor Staging System is based on nodal lymphomas
such as Hodgkin’s lymphoma and B-cell lymphoma. In con-
trast to extranodal B-cell lymphoma which usually forms a
single mass, multifocal or diffuse ulcerative involvement of
one or two anatomical segments of the intestine is a common
finding in NK or T cell lymphoma (17). In Ann-Arbor Stag-
ing System, diffuseness or multifocality of the lesion in NK
or T-cell lymphoma are not taken into account, which can
lead to underestimation of the tumor stage.
It is difficult to establish the definite prognostic significance
of marrow involvement in nasal type NK/T cell lymphoma
because of the aggressive nature of the disease with very short
survival time in the majority of patients and the small num-
ber of cases with marrow involvement. In this study, all three
patients with bone marrow involvement died of the disease.
In conclusion, minimal involvement of bone marrow is
infrequent in nasal-type NK/T cell lymphoma. And EBER
ISH is a useful technique for identifying minimal involve-
ment of bone marrow by nasal-type NK/T cell lymphoma,
which is easily overlooked but closely related with poor prog-
nosis.
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